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Abstract
Background: Cervical cancer is due to infection with specific high-risk types of human papillomavirus
(HPV). Although the incidence of genital HPV infection in various population groups is high, most of these
regress without intervention. Investigating genetic host factors and cellular immune responses, particularly
cytokines, could help to understand the association between genital HPV infection and carcinogenesis. The
tumor necrosis factor alpha (TNF-α) cytokine plays an important role in all stages of cervical cancer and
has the ability to induce the regression of human tumors. Therefore the aim of the study was to investigate
the allelic distribution of -308 TNF-α gene polymorphism in South African women with cervical cancer
compared to control women.
Methods: Included in our study were women with histologically proven cancer of the cervix (n = 244)
and hospital-based controls (n = 228). All patients and controls were from mixed race and black
population groups in South Africa. The detection of a bi-allelic -308 (A/G) polymorphism in the promoter
region of TNF-α was investigated using the amplification refractory mutation system-polymerase chain
reaction (ARMS-PCR) technique. The distributions of the allelic frequencies were stratified in both
patients and controls into two South African ethnic population groups.
Results: In this study we observed no association between the distribution of -308 TNF-α polymorphism
and the risk of developing cervical cancer even after combining the data from the two ethnic populations
(X2 = 2.26). In addition, using the chi-squared test we found no significant association between the known
risk factors for cervical cancer and the allele distribution of -308 TNF-α. However, the frequency of the
rare high-producing allele -308A of TNF-α was significantly lower in the South African population when
compared to Caucasians and Chinese population groups.
Conclusion: We demonstrated no association between -308 TNF-α polymorphism and the risk of
cervical cancer among two South African ethnic population groups. However, as the distribution of the -
308A TNF-α was notably different between the control groups of South Africa and other population
groups this result suggests that ethnic disparity may influence the levels of TNF-α produced.
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Background
There is strong epidemiological and experimental data
that have demonstrated a definite association of high-risk
human papillomavirus (HR-HPV) infection and the
development of cervical cancer [1]. Interestingly,
although most sexually active women in the normal pop-
ulation have asymptomatic cervical HPV infections, most
of these cervical infections are transient, with clearance in
70% to 90% of individuals positive for HPV DNA. In
addition, only a small percentage develops long-term
HPV infection, which is associated with an increased risk
of developing cervical cancer [2]. Thus, an effective host
immune response may be an important determinant for
the persistence and progression of HPV induced cervical
cancer. In particular, cell-mediated immunity (CMI) is
important in controlling both HPV infections and HPV-
associated neoplasms [3]. CMI is regulated by cytokines
that are secreted primarily by T helper (Th) cells and mac-
rophages.
Cytokines play a significant role in the defense against
HPV induced infections, modulating viral replication and
polarizing the immune response to a Th1 (cellular) or Th2
(humoral) pattern [1]. Th1 cells are immuno-stimulatory
and are associated with the clearance of HPV infection
and regression of cervical intraepithelial neoplasia [4] Th2
cells are immuno-inhibitory and are capable of stimulat-
ing tumor growth [5]. Investigating genetic host factors
and immune responses could help to understand the
association between genital HPV infection and carcino-
genesis [6], as cervical cancer is the second most common
female cancer worldwide and the most common cancer in
South Africa among women, which continues to be a pub-
lic health burden. Several candidate gene studies have
demonstrated that genetic polymorphisms in cytokine
genes contribute to the variation in the levels of cytokine
produced and this variation may influence the severity of
several infectious diseases [7-9]. Among them the pro-
inflammatory cytokine, tumor necrosis factor-alpha
(TNF-α) has been of particular interest as it was found to
be located in the central major histocompatibility com-
plex (MHC) and a possible genetic correlation between
TNF alleles and disease susceptibility was hypothesized
[10].
TNF-α is a multifunctional cytokine that was originally
identified as a macrophage-derived serum protein that
mediates necrosis of solid tumors in vitro and in vivo
[11]. In addition, TNF has been shown to mediate car-
cinogenesis through induction of proliferation, invasion,
and metastasis of tumor cells [12]. Furthermore, it was
shown that the expression of TNF-α is regulated at the
transcriptional level [13] and various polymorphisms
within the TNF-α promoter region have been associated
with the level of TNF-α produced [10,14,15]. Several
investigators have studied the polymorphisms within the
TNF-α promoter region to estimate the immune responses
to a wide range of cancers [9,16,17] including cervical can-
cer [18,19]. In particular, the biallelic polymorphism in
the promoter region at position -308 relative to the tran-
scriptional start site of the gene, representing a transition
from the nucleotides guanine (G) to adenine (A) has been
commonly studied. This -308G/A transition affects the
expression of TNF-α where the less common -308A allele
produces higher levels of TNF-α, while the -308G allele is
linked to a reduced TNF-α production [10,20]. Indeed,
these observations presented the possibility that tumor
development may be associated to the genetic predisposi-
tion of the host to produce higher levels of TNF-α. Numer-
ous studies have investigated the association between the
effect of TNF-α promoter region and cervical cancer, but
the results have been contradictory [9,18,21,22]. Notably,
these findings are from different population groups and
thus indicate that the variation in TNF-α production may
be influenced by the genetic make-up of diverse popula-
tion groups contributing to a disparity in disease out-
come.
Therefore, given the importance of TNF-α in potentially
contributing to the progression of cervical cancer with var-
iations in the levels of TNF production in different popu-
lation groups, we investigated the biallelic polymorphism
in the -308 promoter region of the TNF-α gene using the
ARMS-PCR methodology and examined its relationship
to the development of cervical cancer among two South
African ethnic groups.
Methods
Patients and control populations
Individuals were selected from a case-control study of can-
cer of the cervix and related risk factors conducted among
colored (mixed racial descent) and black women residing
in the Western Cape Province of South Africa, from Janu-
ary 1998 to December 2001 [23]. The Research Ethics
Committee, Faculty of Health Sciences, University of Cape
Town, South Africa, approved the case-control study.
Cases were women with invasive cancer of the cervix
attending Gynae-oncology clinics at 2 tertiary hospitals.
The controls, who were hospital based, were women with
primary diagnosis such as trauma or acute infections that
were judged to be independent of contraceptive use and
had no history or evidence of cervical disease and were
identified at the 2 tertiary hospitals. The controls were
series matched to cases for decade age, ethnic group and
area of residence. Data on known risk factors and poten-
tial confounders were collected using a detailed question-
naire administered by trained nurse interviewers.
Papanicoloau (Pap) smears were taken from all control
women. Blood samples from randomly selected 244 eligi-
ble cervical cancer patients and 228 hospital-based con-BMC Cancer 2006, 6:24 http://www.biomedcentral.com/1471-2407/6/24
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trols were analysed for the -308 polymorphisms in the
promoter region of TNF-α.
DNA extraction
Genomic DNA was extracted from 200 µl of whole blood
using the QiAamp Spin Blood Kit (QIAGEN, Valencia,
CA) in accordance with manufacturer's instructions.
Cytokine genotyping
The A and G alleles at position -308 in the promoter
region of the TNF-α gene were identified using the ampli-
fication refractory mutation system polymerase chain
reaction (ARMS-PCR) methodology as previously
described [24]. A total of 2 ul (25–100 ng) of DNA was
used in each ARMS-PCR reaction. The PCR primer
sequences were as follows:
Generic primer (antisense): 5'-tctcggtttcttctccatcg-3'
Primer G, allele1 (sense): 5'-ataggttttgaggggcatgg-3'
Primer A, allele2 (sense): 5'-aataggttttgaggggcatga-3'
The amplified ARMS-PCR products (PCR product size =
184 bp) were identified by gel electrophoresis on 2 % aga-
rose gels stained with ethidium bromide.
Statistical analysis
Statistical analyses were performed using STATA version 8.
The allele frequency of the -308 TNF-α polymorphism
was compared between the patients and control groups
using the X2 test. Unconditional logistic regression was
used to estimate odds ratios (OR's) for developing cancer
of the cervix in relation to the -308 TNF-α gene polymor-
phism. These OR's were adjusted for the following con-
founding factors; ethnic group, 5 year age group, years of
education, age at first sexual intercourse, number of sexual
partners, urban/rural living, number of Pap smears, inject-
able/oral contraceptive use, smoking, and parity.
Results
To evaluate the accuracy of the assigned TNF-α genotypes
a total of twenty-five samples were randomly chosen and
the results were confirmed by repeating the ARMS-PCR.
Notably there were no discrepant results detected when
the ARMS-PCR assay was repeated on the samples.
The genotype distribution of the polymorphism at posi-
tion -308 of the TNF-α promoter region in the cases and
controls among the two South African ethnic groups are
shown in Table 1. There were no significant differences in
the distribution of TNF-α allelic polymorphisms and the
risk of developing cervical cancer in the mixed race group,
(OR, 2.93; 95% CI, 0.51–16.72) or the black group (OR,
0.87; 95% CI, 0.27–2.76). In addition, when the data was
adjusted for potential confounding factors (adjusted for 5
year age group, education, age at first sex, number of sex-
ual partners, number of Pap smears, injectable/oral con-
traceptive use, smoking, and parity), no significant
association was observed (data not shown).
As there were no significant differences in the distribution
of the -308 TNF-α alleles in the cervical cancer patients
among the two South African ethnic populations, the data
was combined to compare allele distributions to other
population groups (Table 2). Interestingly, the genotype
distribution of the -308 TNF-a genotypes for the South
African cancer cases were different to those reported in a
Korean population group (homozygous GG 71% vs 90%;
and heterozygous AG 26% vs 6%). In addition, the distri-
butions of the -308 TNF-α alleles in the two South African
control groups were combined to compare the genotype
distribution to other population groups (Table 3). The
genotype distribution for the homozygous GG and AA -
Table 1: Odds Ratios and 95% confidence intervals (CI) for the development of cervical cancer in relation to -308 TNF-α alleles among 
the cervical cancer cases and controls in the two South African ethnic population groups.
Race Genotype CaCx n (%) Controls n (%) OR1 (95%CI)
1. All# (n = 244) (n = 228)
GG 174 (71) 172 (76) 1.29 (0.49 – 3.37)
AG 62 (26) 46 (20) 1.80 (0.66 – 4.97)
AA 8 (3) 10 (4) 1
2. Mixed race (n = 83) (n = 59)
GG 64 (77) 45 (76) 2.93 (0.51–16.72)
AG 17 (21) 10 (17) 3.78 (0.58–24.75)
AA 2 (2) 4 (7) 1
3. Black (n = 161) (n = 169)
GG 110 (68) 127 (72) 0.87 (0.27–2.76)
AG 45 (28) 36 (24) 1.25 (0.37–4.21)
AA 6 (4) 6 (4) 1
#All (1) = Mixed race (2) and Black (3) population groups combined
OR1 = crude odds ratio adjusted for ethnic group in the combined ethnic group analysisBMC Cancer 2006, 6:24 http://www.biomedcentral.com/1471-2407/6/24
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308 genotypes for the combined South African data were
similar to those reported in Zimbabwean [21], Chinese
[25]; Italian [26] and Korean [14] populations. However,
the distribution of the heterozygous AG genotype was
notably different in the Chinese and Korean compared to
the South African control group (8% versus 20 %). In
addition, there was an increased frequency of the -308
TNF-α A allele and decrease in the G allele in the British
Caucasoid group [24] when compared to the South Afri-
can population group.
Discussion
Although the Pap smear screening has reduced cervical
cancer mortality in developed countries, 35000 women
die from this disease every year in the United States and
Europe [27]. The current treatments for cervical cancer are
invasive, costly, limited, uncomfortable, inefficient and
recurrence is a common outcome [28]. There are several
prophylactic and therapeutic clinical HPV vaccine trials
that are in progress [29,30], which may assist in reducing
this disease burden worldwide. However, while these
strategies are commendable it is important to investigate
other host or viral markers that contribute to the different
stages of cervical disease and thus may provide an effective
tool for the treatment of cervical cancer. It is accepted that
persistent HRHPV-induced infection is the hallmark of
cervical cancer.
Indeed, other co-factors such as viral load, lifestyle factors,
high parity, smoking, long-term use of contraceptives and
other sexually transmitted diseases have also been estab-
lished as risk cofactors for cervical cancer among women
with persistent HPV infections [31]. In addition, several
studies have indicated that the polymorphisms in the pro-
moter region of -308 TNF-α may be a contributing factor
for the development of cervical cancer [18,21,32]. How-
ever, the results of these studies have been contradictory.
Thus in the present study we sought to identify the possi-
ble link between -308 A/G TNF-α allele polymorphism
and the progression of cervical cancer among two ethnic
population groups in South Africa. We found no signifi-
cant differences between the -308TNF-α allele polymor-
phism and cervical cancer risk among the two South
African ethnic population groups. In addition we
observed no significant differences in the distribution of
the high (AA), medium (AG) or low (GG) genotypes of
TNF-α among the South African cervical cancer patients
and healthy controls (and in the combined race groups)
(X2 = 2.26) even when the data were adjusted for potential
confounders (data not shown).
The findings in our study are similar to those reported by
Stanczuk et al., [21], who investigated the association of -
308TNF-α gene polymorphism with cervical cancer
among a Zimbabwean population [21]. They found no
significant differences in the distribution of the high,
medium or low producing alleles in the cervical cancer
patients and healthy women. However, their study was
based on a small sample size and the authors suggested
that a larger cohort should be investigated to challenge
this association, as their lack of association using a small
sample size may have affected the statistical power of the
study. Although our study included a large sample size we
were unable to confirm this possibility and found no cor-
relation between -308 TNF-α polymorphism and the risk
of developing cervical cancer among the South African
population. Similar reports were documented by others
[9,22,33] and discordant with those previously reported
Table 2: Distribution (%) of -308 TNF-α genotypes in women with cervical cancer among different population groups.
Genotype *South African n = 244 n (%) +Korea (South) n = 51 n (%) †USA n = 127 n (%) §Zimbabwe n = 103 n (%)
GG 174 (71) 46 (90) 91 (72) 74 (72)
AG 62 (26) 3 (6) 27 (21) 28 (27)
AA 8 (3) 2 (4) 9 (7) 1 (1)
*Combined Black and mixed race cancer case groups in this study (There were no differences in the distribution of the -308 TNF-α alleles between 
the two South African ethnic populations, thus the data was combined to compare genotype distributions to other population groups).
Data reported by; +[14]; †[9]; §[21].
Table 3: Distribution (%) of -308 TNF-α genotypes in the combined South African control population groups and other populations.
Genotype *South African 
n = 228 n (%)
^China (North) 
n = 300 n (%)
#Italy (North) 
n = 216 n (%)
+Korea (South) 
n = 92 n (%)
†Manchester 
n = 106 n (%)
§Zimbabwe 
n = 101 n (%)
GG 172 (78) 274 (91) 172 (80) 85 (92.4) 65 (61) 81 (80)
AG 46 (20) 24 (8) 41 (19) 7 (7.6) 24 (23) 18 (18)
AA 10 (4) 2 (0.7) 3 (1) 0 17 (16) 2 (2)
*Combined Black and mixed race control groups in this study (There were no differences in the distribution of the -308 TNF-α alleles between the 
two South African ethnic populations, thus the data was combined to compare genotype distributions to other population groups).
Data reported by ˆ[25]; #[26]; +[14]; †[24]; §[21].BMC Cancer 2006, 6:24 http://www.biomedcentral.com/1471-2407/6/24
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in a population group from the United Kingdom [15]. In
their study the authors demonstrated that the polymor-
phism in -308TNF-α gene significantly increased the sus-
ceptibility to cervical intraepithelial neoplasia 1 (CIN 1).
However, as it is well-documented that most CIN1 regress
spontaneously [34] it would have been beneficial if the
authors extended the follow up screening to 36 months
and thus the positive association demonstrated by the
authors should be regarded with caution. In addition,
CIN1 includes very mild to mild dysplasia, which is char-
acterized by 20–25% replacement of the epithelium with
immature cells and generally requires no treatment [29].
Furthermore, although in the same study the recruited
subjects were age matched the authors did not provide the
ethnic background for the population studied [15]. Thus,
it is difficult to conclusively confirm or refute the possible
ethnic disparity that may have contributed to the associa-
tion differences observed between our study population
and theirs.
Several reports in cervical cancer survival studies have
indicated that the higher mortality rate in black popula-
tions is explained primarily by the more advanced clinical
stage at time of diagnosis [35,36]. It was found that the
percentage of early diagnosis among blacks and Hispanics
were significantly low for cervical and breast cancer com-
pared to non-Hispanics whites. It was therefore suggested
that screening programs should be managed differently
for specific ethnic groups as there is a significant disparity
in the outcome of disease between ethnic populations.
[36]. Indeed, the high incidence of cervical cancer in cer-
tain population groups may be due to poor screening pro-
grams, a lack of stringent follow-up treatments and lower
socioeconomic status in different population groups. In
the present study, we compared our cervical cancer patient
group with those from other populations (Table 2).
Although there was a difference in the distribution of the
GG and AG of TNF-α between our study and the Korean
population, this result should be taken with caution as the
sample size for the Korean population was very small. It
would therefore be valuable if the samples size was
increased to examine these relationships adequately. Nev-
ertheless, 26% vs 6% is significant. Furthermore, we com-
pared the distribution of our control study group to those
of other populations to identifying whether the distribu-
tion of the TNF-α gene at position -308 is different in
other healthy population groups (Table 3). The distribu-
tion of the AATNF-α, GGTNF-α and AGTNF-α genotypes
at position -308 in the present control study group were
similar to those observed in a Zimbabwean and Italian
population and differed from those found in a Caucasian
group. In addition, the distribution of the AGTNF-α gen-
otype in the South African population group differed
from that found in a Chinese and Korean population.
These data highlight the possible variability of cytokine
gene frequencies in different population groups and
hence influence the disease outcome.
Conclusion
It is important to identify host or viral genetic markers
that may facilitate the risk of developing cervical cancer. In
addition, these markers would be useful in providing
effective treatments and preventative strategies against
HPV-induced infections. However, in this study we found
no association between -308 TNF-α gene polymorphism
and the risk of developing cervical cancer. Furthermore,
our data highlight the need for further studies to clarify
the association of ethnic variation and cytokine polymor-
phism as other potential confounding factors may con-
tribute to the risk of developing cancer of the cervix.
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